FindTrial
Sign In

To evaluate the role of methylene blue in reducing the requirement of vasopressor(norepinephrin)in patients suffering from septic shock(patients aged 18-70 years with septic shock as defined by Sepsis-3 criteria) .

To determine role of methyleneblue in septic shock as a vasopressor sparing agent:a prospective randomized controlled study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/074331
Enrollment
62
Registered
2024-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I959- Hypotension, unspecified Health Condition 2: I999- Unspecified disorder of circulatory system

Interventions

Intervention1: group MB(methylene blue) containing 42 patients each: 1.Patients assigned to MB(M) group will receive an intravenous (IV) infusion of 100 mg of MB in 500 ml of 0.9% sodium chloride solu

Sponsors

Trauma Ventilatory Unit
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult patient aged between 20- 50 year of aged admitted in ICU with septic shock will be included in the study after obtaining written informed consent.

Exclusion criteria

Exclusion criteria: Not giving consent 24 h since initiation of norepinephrine, pregnancy, high probability of death within 48 h APACHE Score 25 concurrent hemorrhagic and cardiogenic Shock obstructive or hypovolemic shock, pending damage control surgery, major burn injury, patient expire within 24 hr allergy to methylene blue,

Design outcomes

Primary

MeasureTime frame
To determine the vasopressor sparing effect of methylene blue in septic shock patients.Timepoint: Norepinephrine dose will be recorded at randomization, immediately after each dose of intervention drug, at 24- and 48-h post-treatment, for a total of 4 days.—

Secondary

MeasureTime frame
28 days mortality Serum lactate level length of stays in ICU Timepoint: 28 dyas—

Countries

India

Contacts

Public ContactProf Zia Arshad

King Georges Medical University Lucknow

ziaarshad13@gmail.com9415722226

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026